Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
Holding OGN?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.87Last Year’s EPS
0.88Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 11, 2021
|% Change Since: -10.67%
|Next Earnings Date:Aug 12, 2021
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth, strategic acquisitions, and solid free cash flow. However, there were some challenges related to adjusted EBITDA margin pressure and pricing headwinds.Company Guidance
During the Organon Q3 2024 earnings call, the guidance highlighted several key financial metrics and strategic initiatives. Organon reported a revenue of $1.6 billion for the quarter, marking a 5% growth at constant currency, with the Women's Health franchise growing by 6%, Biosimilars by 17%, and Established Brands by 3%. The adjusted EBITDA was $459 million, reflecting a 29% margin, including $51 million of IPR&D expenses. The company raised its full-year revenue guidance midpoint by $50 million, projecting a growth of 1.8% to 2.6% on a nominal basis and 3.1% to 3.8% excluding exchange impacts. The adjusted EBITDA margin guidance for the full year was revised to 30% to 31%. Organon also discussed the acquisition of Dermavant and its asset VTAMA, expected to achieve at least $150 million in sales by 2025, with potential growth to $0.5 billion over the next 3 to 5 years. The transaction is forecasted to be dilutive to EBITDA margin by about 50 basis points in 2025 but accretive in the following year. The company remains on track to generate nearly $1 billion in free cash flow for the year, reflecting strong financial health and strategic positioning.Revenue Growth Across Key Segments
For the third quarter of 2024, revenue was $1.6 billion, representing a 5% growth rate at constant currency. The Women's Health franchise grew 6%, the Biosimilars franchise grew 17%, and the Established Brands franchise was up 3%.
Strong Free Cash Flow
Year-to-date, Organon generated nearly $700 million of free cash flow and is on track to deliver approximately $1 billion of free cash flow before onetime costs in 2024.
Acquisition of Dermavant
Organon acquired Dermavant and its key asset VTAMA, a nonsteroidal topical cream, which is expected to achieve at least $150 million of sales in 2025, with potential growth to $0.5 billion over the next 3 to 5 years.
Positive Outlook for NEXPLANON
NEXPLANON grew 18% in the U.S. in the third quarter and is expected to achieve constant currency full year revenue growth in the low to mid-teens, positioning it to reach $1 billion in revenue next year.
---
OGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $17.62 | $18.45 | +4.71% |
| Aug 06, 2024 | $19.56 | $18.07 | -7.62% |
| May 02, 2024 | $18.00 | $18.64 | +3.56% |
| Feb 15, 2024 | $15.40 | $17.53 | +13.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Organon (OGN) report earnings?
Organon (OGN) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Organon (OGN) earnings time?
Organon (OGN) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OGN EPS forecast?
OGN EPS forecast for the fiscal quarter 2024 (Q4) is 0.87.
---